Trial intelligence / Profile preview

Phase IIb randomized double-blind placebo-controlled dose-finding study of BAY 3283142 in chronic kidney disease

CTR20242548Phase 2Completed

Sponsor
Bayer
Start
Aug 2024
Modality
Small Molecules
Countries
1
01

Overview

A Phase 2 trial of BAY3283142 in chronic kidney disease (CKD), sponsored by Bayer. Started Aug 2024; status: completed.

02

Drugs

BAY3283142
03

Conditions

chronic kidney disease (CKD)

Beyond the preview

Go deeper on CTR20242548.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on CTR20242548.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call